FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Machinatan	D C	20540	
Nashington,	D.C.	20049	

TATEMENT	OF CHAN	<b>GES IN BEI</b>	NEFICIAL O	WNERSHIP

OMB APPROVAL									
OMB Number: 3235-028									
Estimated average	burden								
hours per response	e· 0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  LASEZKAY GEORGE M					2. Issuer Name and Ticker or Trading Symbol Clearside Biomedical, Inc. [ CLSD ]								all app Direc	tor	ng Pers	10% O	wner		
		st) (N BIOMEDICAL, I		00	3. Date of Earliest Transaction (Month/Day/Year) 09/22/2020						X	Office below	,	ЕО	Other ( below)	specify			
(Street) ALPHA	RETTA GA		0005 Zip)		4. If <i>F</i>	Line							6. Indiv _ine) X	·					
		Table	I - No	n-Deriva	tive S	Secui	rities	Acq	uired,	, Dis	posed of	, or B	enefic	ially	Own	ed			
1. Title of Security (Instr. 3)  2. Transact Date (Month/Day			Execution Date,		3. Transaction Code (Instr. 8)  4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5)			4 and Secu Bene Own		rities For ficially (D and Following (I)		nership : Direct · Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)						
						Code	v	Amount	(A) or (D) Pri		е	Transa	Reported Transaction(s) (Instr. 3 and 4)			(11150.4)			
Common	Stock			09/22/2	020 s <sup>(1)</sup> 13,411		D	\$1.	<b>59</b> <sup>(2)</sup>	302,689(3)			D						
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
Derivative Security (Instr. 3) Conversion or Exercise Price of Derivative Security Execution Date, if any (Month/Day/Year)		4. Transa Code ( 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)  Date Expiration Exercisable Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		Der Sec (Ins	Price of ivative urity str. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	y C	0. Ownership Form: Direct (D) or Indirect I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)				

## **Explanation of Responses:**

- 1. The sales reported in this Form 4 represents shares required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction pursuant to a Rule 10b5-1 trading plan.
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$1.56 to \$1.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 3. Includes 5,000 shares acquired under the Issuer's employee stock purchase plan on June 30, 2020.

## Remarks:

/s/ Mark Ballantyne, Attorney- 09/24/2020 in-Fact

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.